ArticleThe Journal of thoracic and cardiovascular surgery2017
Preclinical study of patient-specific cell-free nanofiber tissue-engineered vascular grafts using 3-dimensional printing in a sheep model.
Article in The Journal of thoracic and cardiovascular surgery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04325789 (A Prospective Randomized Multicenter Evaluation of Rotator Cuff Healing Using a Nanofiber Scaffold in Patients Greater Than 55 Years), which is not on this map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Randomized Multicenter Evaluation of Rotator Cuff Healing Using a Nanofiber Scaffold in Patients Greater Than 55 Years
Who cites it
50 citing papers in PubMed.
- Hematologic complications and design challenges in cardiovascular devices.Communications engineering · 2026Review
- A Translational Paradigm for Univentricular Heart Disease: Single-Stage Neonatal Repair with Adaptive Control of Cavopulmonary Flow.Cardiovascular engineering and technology · 2026Article
- Barriers to clinical translation of small-diameter tissue-engineered vascular grafts in peripheral reconstruction.JVS-vascular science · 2026Review
- Biomechanical enhancement in rotator cuff repairs: the impact of innovative nanofiber technology.JSES international · 2025Article
- Leveraging printability and biocompatibility in materials for printing implantable vessel scaffolds.Materials today. Bio · 2024Review
- Recent Advances in Hydrogel-Based 3D Bioprinting and Its Potential Application in the Treatment of Congenital Heart Disease.Biomolecules · 2024Review
- Biomimetic Approaches in Scaffold-Based Blood Vessel Tissue Engineering.Biomimetics (Basel, Switzerland) · 2024Review
- Vascular Damage and Repair - Are Small-Diameter Vascular Grafts Still the "Holy Grail" of Tissue Engineering?Physiological research · 2024Review
- Article
- Nanoparticles as a Novel Platform for Cardiovascular Disease Diagnosis and Therapy.International journal of nanomedicine · 2024Review
- Validity of Customized Branched Tissue Engineered Vascular Graft in a Porcine Model.Annals of thoracic surgery short reports · 2023Article
- Current Strategies for Engineered Vascular Grafts and Vascularized Tissue Engineering.Polymers · 2023Review
- Nanomedicines for cardiovascular disease.Nature cardiovascular research · 2023Review
- Three-dimensional bioprinting of artificial blood vessel: Process, bioinks, and challenges.International journal of bioprinting · 2023Review
- Tween-80 improves single/coaxial electrospinning of three-layered bioartificial blood vessel.Journal of materials science. Materials in medicine · 2022Article
- Location matters: Offset in tissue-engineered vascular graft implantation location affects wall shear stress in porcine models.JTCVS open · 2022Article
- Article
- Semi-Automatic Planning and Three-Dimensional Electrospinning of Patient-Specific Grafts for Fontan Surgery.IEEE transactions on bio-medical engineering · 2022Article
- Electrospun hybrid nanofibers: Fabrication, characterization, and biomedical applications.Frontiers in bioengineering and biotechnology · 2022Review
- Strategies to counteract adverse remodeling of vascular graft: A 3D view of current graft innovations.Frontiers in bioengineering and biotechnology · 2022Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors.
Funding
Abstract
backgroundTissue-engineered vascular grafts (TEVGs) offer potential to overcome limitations of current approaches for reconstruction in congenital heart disease by providing biodegradable scaffolds on which autologous cells proliferate and provide physiologic functionality. However, current TEVGs do not address the diverse anatomic requirements of individual patients. This study explores the feasibility of creating patient-specific TEVGs by combining 3-dimensional (3D) printing and electrospinning technology.
methodsAn electrospinning mandrel was 3D-printed after computer-aided design based on preoperative imaging of the ovine thoracic inferior vena cava (IVC). TEVG scaffolds were then electrospun around the 3D-printed mandrel. Six patient-specific TEVGs were implanted as cell-free IVC interposition conduits in a sheep model and explanted after 6 months for histologic, biochemical, and biomechanical evaluation.
resultsAll sheep survived without complications, and all grafts were patent without aneurysm formation or ectopic calcification. Serial angiography revealed significant decreases in TEVG pressure gradients between 3 and 6 months as the grafts remodeled. At explant, the nanofiber scaffold was nearly completely resorbed and the TEVG showed similar mechanical properties to that of native IVC. Histological analysis demonstrated an organized smooth muscle cell layer, extracellular matrix deposition, and endothelialization. No significant difference in elastin and collagen content between the TEVG and native IVC was identified. There was a significant positive correlation between wall thickness and CD68
conclusionsCreation of patient-specific nanofiber TEVGs by combining electrospinning and 3D printing is a feasible technology as future clinical option. Further preclinical studies involving more complex anatomical shapes are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.